Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617279 · ClinicalTrials.gov registry record · Phase 4
GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft
A Phase 4 study, sponsored by W.L.Gore & Associates.
- Terminated
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT00617279: Clinical Trial Phase 4 study, sponsored by W.L.Gore & Associates.
NCT00617279 is a Phase 4 study that was terminated before completion, run by W.L.Gore & Associates. The registered enrollment target is 31 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00617279, a Phase 4 study, was terminated before completion, sponsored by W.L.Gore & Associates.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.
Primary Outcome
Primary patency is defined as hemodynamic evidence of blood flow through an open graft that has maintained uninterrupted patency and has not previously undergone a revision to restore blood flow.
Interventions
- DEVICE GORE PROPATEN Vascular Graft
- PROCEDURE Disadvantaged Autologous Vein Graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 4 |
Why NCT00617279 stopped before completion
NCT00617279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which GORE PROPATEN Vascular Graft is the first listed.
NCT00617279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00617279 about?
NCT00617279 is a clinical study titled "GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft". The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.
What is the current status of trial NCT00617279?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2007-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00617279?
The interventions under investigation include: GORE PROPATEN Vascular Graft (DEVICE), Disadvantaged Autologous Vein Graft (PROCEDURE).
Who is sponsoring clinical trial NCT00617279?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00617279's enrollment target sits among peer trials
31 1544th of 2000 higher than 449 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia